Health Care
Morgan Stanley among investors buying stake in Turkish drugmaker

(Bloomberg) –Morgan Stanley and a group of investors are close to buying 30% of Turkish drugmaker Sanovel Ilac Sanayi ve Ticaret AS, according to people with knowledge of the matter.
London-based buyout firm Metric Capital Partners LLP is also part of the consortium that will pay almost $200 million for the stake in the producer of anti-inflammatory, anti-asthmatic and antibiotic medication, said the people, asking not to be identified because the information isn’t public.
Read: Novartis agrees to buy Medicines Co. in $6.8 billion deal
Representatives for Sanovel, Morgan Stanley and Metric Capital declined to comment. The deal is due to be signed next week, the people said.
The deal follows a failed attempt by Sanovel’s owners, Turkish businessmen Ahmet Toksoz and Zafer Toksoz, to sell a minority holding to Abraaj Group in 2018. The Dubai-based buyout firm, which once managed about $14 billion as the developing world’s most influential private equity investor, was forced into liquidation after mismanaging investor funds.
-
Banking & Finance3 weeks ago
Oman Arab Bank Announces Increase of Authorised Capital to RO500mn and Paid‑In Capital Boost of RO50mn
-
Renewables2 months ago
Jindal Renewables and OQ Alternative Energy Sign Joint Development Agreement to Advance Integrated Renewable Power Projects in Oman
-
Bahrain3 weeks ago
SPIEF 2025 focused on global and regional economic processes, market transformation, new tech, investment climate, financial policy and people
-
OER Magazines2 months ago
OER, May 2025
-
Alamaliktistaad Magazines2 months ago
Al-Iktisaad, May 25
-
Banking & Finance1 month ago
Central Bank of Oman Issues Regulatory Framework for Digital Banks
-
Banking & Finance2 months ago
United Finance Company: Strategically Serving Oman’s Auto Market with Faster, Customer-First Solutions
-
Insurance1 month ago
Liva Insurance Sets New Benchmark with ‘Innovative Insurer of the Year’ Award at the New Age Banking Summit 2025